What an inspiring and productive  9th Steering Committee (SC) Meeting! It was lovely to meet the liver-health enthusiasts and clinical investigators who recently joined our G-TAK Study! The first half of the SC Meeting addressed many questions our valued colleagues from the United Kingdom (UK) and India had. The second half of today's agenda consisted of progress reports from work packages WP1, WP2, WP3, WP7, and WP8, leading to important discussions and decisions. Let's roll up our sleeves now to sign further study site contracts in the UK and India to include as many ACLF patients in this study as possible. Bringing an effective treatment for this dangerous disease to the market is an urgent unmet need because the prevalence of decompensated cirrhosis amounts to approximately 10 million cases per year.

The upcoming Liver Health Helix Event on Wednesday, 04 June 2025, from 11:00 - 12:30 CEST (10:00 - 11:30 BST) about the challenges of drug development for clinical trials is an exciting open innovation event designed to accelerate the development of new treatments for liver diseases, particularly severe alcoholic hepatitis (sAH), advanced cirrhosis, and acute-on-chronic liver failure (ACLF). Taking place in support of the A-TANGO project and related research initiatives, this event brings together leading hepatologists, cirrhosis researchers, industry professionals, and investors to explore the latest breakthroughs, share expertise, and spark impactful collaborations. Now is the time to secure your spot in this vibrant and forward-thinking community. Register here!

Our Liver Health Helix Event on 04 June 2025 features an exceptional lineup of speakers from the fields of hepatology, clinical research, drug development, and bioinformatics. Troels Jordansen, CEO of Yaqrit, Cornelius Engelmann, clinical trial supervisor at the Charité, Burcu Kiper, Impact Acceleration Manager at Crowdhelix, and guest speaker Salvador Augustin from Boehringer Ingelheim will keep you on your toes. They will share valuable insights into the latest therapeutic strategies, innovative approaches, and ways to overcome the challenges of clinical trials. Attendees will benefit from firsthand knowledge, real-world case studies, and opportunities to engage directly with some of the brightest minds in liver disease research and drug development.